Johnson & JohnsonvsProtagonist Therapeutics

JNJ and PTGX stock compared: price, dividend, valuation and results, from SEC filings.

PTGX

Protagonist Therapeutics, Inc.

$121.60

Value $7.8B

-1.95%
PTGX's page

Johnson & Johnson (JNJ) has a market value of $654B and Protagonist Therapeutics (PTGX) $7.8B. Over the last year, with dividends, JNJ moved +36.9% and PTGX +42.8%. The P/E is 40.6 for JNJ and 22.7 for PTGX. Dividend yield: JNJ 1.95%, PTGX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$654B

    PTGX$7.8B

    JNJ is 84 times PTGX

  • Revenue, 12 months

    JNJ$99.3B

    PTGX$552M

    JNJ is 180 times PTGX

  • Net income, 12 months

    JNJ$16.1B

    PTGX$342M

    JNJ is 47 times PTGX

  • Operating margin

    JNJ–

    PTGX58.6%

  • ROIC

    JNJ12.4%

    PTGX33.2%

    20.8 points apart

  • P/E

    JNJ40.6

    PTGX22.7

    JNJ is 1.8 times PTGX

  • Dividend yield

    JNJ2.0%

    PTGX0.0%

    2.0 points apart

  • 5-year return

    JNJ+91.4%

    PTGX+247.1%

    155.7 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+91.4%

PTGX+247.1%

020040020222023202420252026
Returns by period
PeriodJNJWith dividendsPTGXWith dividends
1 year since November 19, 2025+36.9%Price +33.9%+42.8%Price +42.8%
3 years since November 20, 2023+95.5%+25.0% a yearPrice +80.9%+605.3%+91.8% a yearPrice +605.3%
5 years since November 19, 2021+91.4%+13.9% a yearPrice +66.5%+247.1%+28.3% a yearPrice +247.1%
10 years since November 21, 2016+207.3%+11.9% a yearPrice +135.9%+382.5%+17.0% a yearPrice +382.5%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonPTGXProtagonist Therapeutics

Valuation

JNJPTGX
Valuation
Price$271.23$121.60
Market value$654B$7.8B
Enterprise value (EV)$681B$7.0B
P/E40.622.7
P/E, 5-year median21.9–
P/B8.07.2
EV/EBIT38.421.5
Free cash flow yield3.2%1.4%

Results and growth

JNJPTGX
Results and growth
Revenue, 12 months$99.3B$552M
Net income, 12 months$16.1B$342M
Free cash flow, 12 months$20.6B$109M
Earnings per share, 12 months$6.59$5.36
Revenue growth, year on year6.1%-89.4%
Revenue growth a year, past+2.7%over 5 years+10.0%over 5 years
EPS growth a year, past+14.9%over 5 years–

Margins and returns on capital

JNJPTGX
Margins and returns on capital
Gross margin67.6%–
Operating margin–58.6%
Net margin16.2%62.0%
ROIC12.4%33.2%
ROE19.7%44.5%

Balance sheet

JNJPTGX
Balance sheet
Cash$17.2B$800M
Total debt$44.7B$8.6M
Net debt / EBITDA1.1-2.5
Interest cover18.0×–

Dividends and buybacks

JNJPTGX
Dividends and buybacks
Dividend yield2.0%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%–
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or PTGX

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or Protagonist Therapeutics?

By market value, Johnson & Johnson ($654B) is about 84.2 times Protagonist Therapeutics ($7.8B), at today's prices.

How did JNJ and PTGX stock do over the last 10 years?

Since November 21, 2016, JNJ's price moved +135.9% and PTGX's +382.5%. With dividends: JNJ +207.3% (+11.9% a year), PTGX +382.5% (+17.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or PTGX?

The dividend yield at today's price is 1.95% for Johnson & Johnson and none for Protagonist Therapeutics. Over the last twelve months they paid $5.28 and – per share.

What is the P/E of JNJ and PTGX?

At today's price, the P/E is 40.6 for JNJ and 22.7 for PTGX. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Johnson & Johnson or Protagonist Therapeutics?

Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and 62.0% for Protagonist Therapeutics, and the operating margin – and 58.6%. Revenue was $99.3B and $552M.

Which is the better investment, Johnson & Johnson or Protagonist Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.